Sichuan Kelun-Biotech Biopharmaceutical Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Junyou Ge
Chief executive officer
CN¥24.5m
Total compensation
| CEO salary percentage | 21.8% |
| CEO tenure | 4.3yrs |
| CEO ownership | n/a |
| Management average tenure | 3.7yrs |
| Board average tenure | 3yrs |
Recent management updates
Recent updates
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.'s (HKG:6990) 27% Price Boost Is Out Of Tune With Revenues
Apr 13
Analysts Are Upgrading Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) After Its Latest Results
Mar 28Analysts Just Shipped A Notable Upgrade To Their Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) Estimates
Mar 26Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Aug 21We Think Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) Can Easily Afford To Drive Business Growth
Jun 14CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | CN¥25m | CN¥5m | -CN¥267m |
| Sep 30 2024 | n/a | n/a | -CN¥227m |
| Jun 30 2024 | n/a | n/a | -CN¥187m |
| Mar 31 2024 | n/a | n/a | -CN¥354m |
| Dec 31 2023 | CN¥18m | CN¥3m | -CN¥522m |
| Sep 30 2023 | n/a | n/a | -CN¥427m |
| Jun 30 2023 | n/a | n/a | -CN¥333m |
| Mar 31 2023 | n/a | n/a | -CN¥440m |
| Dec 31 2022 | CN¥3m | CN¥2m | -CN¥548m |
Compensation vs Market: Junyou's total compensation ($USD3.39M) is above average for companies of similar size in the Hong Kong market ($USD646.62K).
Compensation vs Earnings: Junyou's compensation has increased whilst the company is unprofitable.
CEO
Junyou Ge (51 yo)
4.3yrs
Tenure
CN¥24,519,000
Compensation
Dr. Junyou Ge serves as an Executive Director of Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. since February 15, 2023 and its Chief Operation Officer since February 2021; General Manager since March 20...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.3yrs | CN¥24.52m | no data | |
| CFO & Joint Company Secretary | 2.8yrs | no data | no data | |
| Deputy GM | 4.4yrs | no data | no data | |
| Deputy GM & Chief Scientific Officer of Large Molecule | 3.8yrs | no data | no data | |
| Deputy GM & Chief Medical Officer | 3.7yrs | no data | no data | |
| Chief Scientific Officer of Small Molecules | 1.3yrs | no data | no data | |
| Joint Company Secretary | less than a year | no data | no data | |
| Deputy General Manager | no data | no data | no data |
3.7yrs
Average Tenure
50yo
Average Age
Experienced Management: 6990's management team is considered experienced (3.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.3yrs | CN¥24.52m | no data | |
| Independent Non-Executive Director | 2.3yrs | CN¥300.00k | no data | |
| Independent Non-Executive Director | 2.3yrs | CN¥300.00k | no data | |
| Non-Executive Director | 8.5yrs | no data | no data | |
| Non-Executive Director | 4.3yrs | CN¥2.63m | no data | |
| Non-Executive Director | less than a year | CN¥1.78m | no data | |
| Non Executive Director | 3.3yrs | no data | no data | |
| Non-Executive Director | 2.8yrs | no data | no data | |
| Independent Non-Executive Director | 2.3yrs | CN¥300.00k | no data | |
| Non-Executive Chairman of the Board | 8.5yrs | no data | no data | |
| Independent Non-Executive Director | 2.3yrs | CN¥300.00k | no data | |
| Chairperson of the Supervisory Committee | 3.3yrs | no data | no data |
3.0yrs
Average Tenure
48.5yo
Average Age
Experienced Board: 6990's board of directors are considered experienced (3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/08 23:52 |
| End of Day Share Price | 2025/05/08 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is covered by 26 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Ziyu He | China International Capital Corporation Limited |
| Yinhao Tang | Citic Securities Co., Ltd. |